GLP-1s may lower risk for death, heart events among people with hidradenitis suppurativa

GLP-1 receptor agonist therapy was associated with lower all-cause mortality among people with hidradenitis suppurativa — a benefit that lasted up to 2 years, according to a study published in JAMA Dermatology.
These findings were consistent even among patients without diabetes who had HS, according to Beata Jastrząb-Miśkiewicz, MD, PhD, a dermatologist, venereologist and lead investigator of the study.
“It suggests that the association between GLP-1 receptor agonists and improved HS outcomes may not be explained only by better glycemic control,” Jastrząb-Miśkiewicz told Healio. “It raises

GLP-1s may improve outcomes in patients with PAD, diabetes

GLP-1s may prevent adverse outcomes in patients with peripheral artery disease and diabetes, according to data published in the Journal of the American Heart Association.
Researchers reported that GLP-1 receptor agonist use among patients with PAD and diabetes was associated with lower risk for mortality, hospitalization, revascularization and amputation compared with those prescribed metformin.
“Obesity and PAD, including chronic limb-threatening ischemia, are linked to increased inflammation, poor blood vessel function, insulin resistance, oxidative stress and faster hardening of the

What LEAD tells us about next era of kidney care

For more than a decade, nephrology has helped define what specialty value-based care can look like in practice.
That journey began in 2015 with the Comprehensive End-Stage Renal Disease Care model and continues today with the Kidney Care Choices (KCC) model. But now, with KCC scheduled to sunset at the end of 2027, value-based kidney care is approaching a critical transition.
In parallel, the CMS Innovation Center (CMMI) released a request for applications for the LEAD (Long-term Enhanced Accountable Care Organization Design) model, marking the next step in CMMI’s primary care-focused

Oral therapy boosts height for children with achondroplasia

A once-daily oral medication raised annualized height velocity for children and adolescents with achondroplasia, according to data from a phase 3 trial published in The New England Journal of Medicine.
As Healio previously reported, infigratinib (BridgeBio Pharma) was granted breakthrough therapy designation by the FDA as a therapy to treat achondroplasia based on findings from a phase 2 trial. In new data from the PROPEL phase 3 trial, researchers reported that the oral therapy conferred a greater increase in annualized height velocity at 1 year than placebo.
“This is very promising evidence

Explore surgical options for gluteus tendon tears

Known as the rotator cuff tear of the hip, gluteus tendon tears are a fairly common injury found mostly among women ranging in age as young as 40 years to as old as 70 years.
Although published literature has reported that gluteus tendon tears occur in 10% to 25% of patients, sources who spoke with Healio said it is one of the most misdiagnosed and underdiagnosed injuries in and around the hip and pelvis.
“It is far more common than you would think,” Jovan R. Laskovski, MD, FAANA, associate professor of orthopedic surgery at Crystal Clinic Orthopaedic Center, told Healio. “It will oftentimes be

Overcoming pulmonary hypertension screening limitations with AI

Diagnosis years after symptoms start is a frequent occurrence in patients with pulmonary hypertension, according to a presentation at the Pulmonary Hypertension Association International PH Conference and Scientific Sessions.
However, AI models can evaluate information from echocardiograms and find patterns that humans cannot see, helping clinicians identify signs of pulmonary hypertension earlier, according to Mohammed Andaleeb Chowdhury, MD, assistant professor of medicine at the Lewis Katz School of Medicine at Temple University.
As Healio previously reported, an AI algorithm had high

Elevated vitamin A positively impacts lung function in asthma

Having higher vs. lower levels of vitamin A was linked to better measures of FEV1 and forced vital capacity in children and adults with asthma, according to results published in Thorax.
“Take your vitamins,” Michael McGeachie, PhD, assistant professor of medicine at Brigham and Women’s Hospital, told Healio.
Using data from two asthma cohorts, McGeachie and colleagues assessed 1,115 children (mean age, 9.2 years; 61% boys) aged 6 to 14 years from the Genetic Epidemiology of Asthma in Costa Rica Study and 1,041 adults (mean age, 58.8 years; 33% men) from the Omic Determinants of Longitudinal

Children, adolescents with cancer can benefit from exercise

Exercise should be part of survivorship planning for children and adolescents with cancer, according to a new American College of Sports Medicine expert consensus statement.
An evidentiary review concluded patients aged 19 years and younger could improve their muscle strength and physical function with concurrent strength and aerobic training, though more research is needed to determine whether exercise benefited other domains, such as cognitive function, depression and fatigue.
“Kids shouldn’t have cancer, but they do, and we need to help them,” Alejandro Lucia, MD, PhD, professor in exercise

Factors unrelated to inflammation may contribute to unacceptable rheumatoid arthritis pain

Female sex, poor baseline patient-reported outcomes and tender vs. swollen joints are significant predictors of unacceptable pain in patients with early rheumatoid arthritis and low inflammation, according to data.
“Despite improved treatment options during the last decades with the achievement of inflammatory control in a growing number of patients, unresolved pain continues to be a major problem in RA,” Anna Eberhard, MD, from the department of clinical sciences at Lund University, in Malmö, Sweden, and colleagues wrote in Annals of the Rheumatic Diseases. “Pain has been